Home › Compound Library › Carvedilol (Coreg)

Carvedilol (Coreg)

Beta Blockerprescriptionoral · predicted

Non-selective beta-blocker with additional alpha-1 blockade (vasodilation) and antioxidant properties. One of three beta-blockers proven to reduce mortality in heart failure (with metoprolol succinate and bisoprolol). Alpha-1 blockade provides vasodilation without reflex tachycardia. Extensive CYP2D6 first-pass metabolism (~25% bioavailability). Must be taken with food to slow absorption and reduce orthostatic hypotension. Dose-titrate slowly in heart failure.

Projected serum levels — 12.5 mg, twice daily

Carvedilol (Coreg)
Carvedilol (Coreg) modeled serum levels, 12.5 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Carvedilol (Coreg) modeled serum levels with a loading dose of 18.4 mg, then 12.5 mg twice daily The first dose is larger so levels approach steady state faster. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 12.5 mg twice daily (oral).

Loading schedule: 18.4 mg on day 1, then 12.5 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 3.7 mg, trough ≈ 1.4 mg body load. Population-based estimate over 15 days for a 12.5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Beta Blocker
Route modeled
Oral
Model confidence
predicted
Half-life
7.5 h
Common dose
12.5 mg
Suggested maximum
50 mg/day
Reference dose range
6.3–50 mg (single dose)
Suggested cadence
twice daily
Validated against
25 mg oral — Cmax 0.080 mg/L at 1.5 h

Documented interactions

  • danger
    Levothyroxine (Synthroid) + Carvedilol (Coreg) Protein binding

    Carvedilol (Coreg) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • danger
    Tacrolimus (Prograf) + Carvedilol (Coreg) Protein binding

    Carvedilol (Coreg) may displace Tacrolimus (Prograf) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • danger
    Warfarin (Coumadin) + Carvedilol (Coreg) Protein binding

    Carvedilol (Coreg) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • warning
    Apigenin + Carvedilol (Coreg) Protein binding

    Apigenin may displace Carvedilol (Coreg) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Carvedilol (Coreg) Protein binding

    Carvedilol (Coreg) may displace Aripiprazole (Abilify) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Armour Thyroid (Desiccated Thyroid Extract) + Carvedilol (Coreg) Protein binding

    Carvedilol (Coreg) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 299 modeled interaction pairings for carvedilol (coreg) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS trial) Packer M et al. · New England Journal of Medicine, 2001 DOI

    Landmark RCT (2289 patients) stopped early: carvedilol reduced mortality by 35% in severe HF (EF <25%), establishing beta-blocker benefit even in NYHA class III-IV heart failure.

  2. Carvedilol versus metoprolol in heart failure: the COMET trial Poole-Wilson PA et al. · Lancet, 2003 DOI

    Head-to-head RCT (3029 patients, 58 months) finding carvedilol reduced all-cause mortality by 17% versus metoprolol tartrate in chronic HF, though the comparison used short-acting metoprolol rather than succinate.

2 published studies referenced in the app, each with a plain-language summary.